Choose a country to view content specific to your location
Choose a country to view content specific to your location
DNA基因分型是一种非常重要的分子诊断技术，可以识别可能导致某些疾病风险增加的遗传变异。基因分型在伴随诊断中发挥着重要作用，可以对患者的基因谱进行表征，帮助指导治疗决策。
本次直播中，讲重点介绍迈迪安全新研发的两种分子qPCR预混液，用于直接从临床样本(如血液、血浆或FFPE组织)中基于PCR检测进行突变鉴定，免除DNA提取，并简化液体和组织活检的检验过程。
主讲嘉宾：
Alpha Chen 迈迪安生物科技市场&产品技术
Steve Hawkins 迈迪安生物科技分子产品经理
液体活检正迅速成为精准医疗领域癌症诊断的首选方法，肿瘤学家可以用于靶向治疗、监测耐药性并检测最小残留病变，而无需患者接受侵入性手术。
本次线上专题讨论会将回顾液体活检是如何为癌症检测、个性化癌症治疗的持续监测以及癌症标记物的治疗耐药性筛选开辟新途径的。分子诊断学领域的四位行业领袖将齐聚一堂，讨论用于癌症筛查的液体活检的现状，以及现代技术如何改变癌症检测和CDx的前景。
主讲嘉宾：
Shidong Jia PhD (CEO, Predicine, USA)
Chris Sale PhD (CEO, Nonacus, UK)
Hongjun (Harry) Yang, PhD (Senior VP of CDx, DiaCarta, USA)
Florent Chang-Pi-Hin PhD (VP of R&D, Meridian Bioscience, USA)
Meridian offers diagnostic manufacturers the complete solution with over 3,000 antigens and antibodies covering more than 500 diseases and an extensive range of specialty qPCR/RT-qPCR master mixes and molecular enzymes all manufactured under ISO13485 regulations.
Have questions about a product? Want to learn more about Meridian’s molecular or immunoassay reagent portfolio? We want to hear from you!
By submitting your information in this form, you agree that your personal information may be stored and processed in any country where we have facilities or service providers, and by using our “Contact Us” page you agree to the transfer of information to countries outside of your country of residence, including to the United States, which may provide for different data protection rules than in your country. The information you submit will be governed by our Privacy Statement.
